» Articles » PMID: 36065090

Fabrication of Nanostructured Lipid Carriers Ocugel for Enhancing Loratadine Used in Treatment of COVID-19 Related Symptoms: Statistical Optimization, , , and Studies Evaluation

Overview
Journal Drug Deliv
Specialty Pharmacology
Date 2022 Sep 6
PMID 36065090
Authors
Affiliations
Soon will be listed here.
Abstract

Loratadine (LORA), is a topical antihistamine utilized in the treatment of ocular symptoms of COVID-19. The study aimed to develop a Loratadine Nanostructured Lipid Carriers Ocugel (LORA-NLCs Ocugel), enhance its solubility, trans-corneal penetrability, and bioavailability. full-factorial design was established with 2 trials to investigate the impact of several variables upon NLCs properties. LORA-NLCs were fabricated by using hot melt emulsification combined with high-speed stirring and ultrasonication methods. All obtained formulae were assessed in terms of percent of entrapment efficiency (EE%), size of the particle (PS), zeta potential (ZP), as well as release. Via using Design Expert® software the optimum formula was selected, characterized using FTIR, Raman spectroscopy, and stability studies. Gel-based of optimized LORA-NLCs was prepared using 4% HPMC k100m which was further evaluated in terms of physicochemical properties, Ex-vivo, and In-vivo studies. The optimized LORA-NLCs, comprising Compritol 888 ATO, Labrasol, and Span 60 showed EE% of 95.78 ± 0.67%, PS of 156.11 ± 0.54 nm, ZP of -40.10 ± 0.55 Mv, and Qh6% of 99.67 ± 1.09%, respectively. Additionally, it illustrated a spherical morphology and compatibility of LORA with other excipients. Consequently, gel-based on optimized LORA-NLCs showed pH (7.11 ± 0.52), drug content (98.62%± 1.31%), viscosity 2736 cp, and Q12% (90.49 ± 1.32%). LORA-NLCs and LORA-NLCs Ocugel exhibited higher ex-vivo trans-corneal penetrability compared with the aqueous drug dispersion. Confocal laser scanning showed valuable penetration of fluoro-labeled optimized formula and LORA-NLCs Ocugel through corneal. The optimized formula was subjected to an ocular irritation test (Draize Test) that showed the absence of any signs of inflammation in rabbits, and histological analysis showed no effect or damage to rabbit eyeballs. C and the AUC were higher in LORA-NLCs Ocugel compared with pure Lora dispersion-loaded gel The research findings confirmed that NLCs could enhance solubility, trans-corneal penetrability, and the bioavailability of LORA.

Citing Articles

Lyophilized Nasal Inserts of Atomoxetine HCl Solid Lipid Nanoparticles for Brain Targeting as a Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD): A Pharmacokinetics Study on Rats.

Teaima M, El-Nadi M, Hamed R, El-Nabarawi M, Abdelmonem R Pharmaceuticals (Basel). 2023; 16(2).

PMID: 37259468 PMC: 9958713. DOI: 10.3390/ph16020326.

References
1.
Sarheed O, Shouqair D, Ramesh K, Amin M, Boateng J, Drechsler M . Physicochemical characteristics and permeation of loratadine solid lipid nanoparticles for transdermal delivery. Ther Deliv. 2020; 11(11):685-700. DOI: 10.4155/tde-2020-0075. View

2.
Danthuluri V, Grant M . Update and Recommendations for Ocular Manifestations of COVID-19 in Adults and Children: A Narrative Review. Ophthalmol Ther. 2020; 9(4):853-875. PMC: 7558551. DOI: 10.1007/s40123-020-00310-5. View

3.
Zheng J, Shang Y, Wu Y, Zhao Y, Chen Z, Lin Z . Loratadine inhibits virulence and biofilm formation. iScience. 2022; 25(2):103731. PMC: 8783127. DOI: 10.1016/j.isci.2022.103731. View

4.
Tang Y, Dou R, Liu Y, Xie S, Han Q . Loratadine-associated cystoid macular edema: A case report. Am J Ophthalmol Case Rep. 2022; 26:101477. PMC: 8935523. DOI: 10.1016/j.ajoc.2022.101477. View

5.
El-Emam G, Girgis G, Hamed M, Soliman O, Abd El Gawad A . Formulation and Pathohistological Study of Mizolastine-Solid Lipid Nanoparticles-Loaded Ocular Hydrogels. Int J Nanomedicine. 2021; 16:7775-7799. PMC: 8627895. DOI: 10.2147/IJN.S335482. View